Patients were randomized 1:1:2 to continue natalizumab , to switch to placebo , or to receive alternative immunomodulatory therapy ( other therapies : IM interferon -1 a [ IM IFN -- 1a ] , glatiramer acetate [ GA ] , or methylprednisolone [ MP ] ) .